Tests a new eye-drop device in people with glaucoma or high eye pressure
Compares a Nanodropper device with regular droppers for eye drops in glaucoma.
Plain-language title generated from the registry record
Registry title: Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
Key facts
- Where
- Lackland Air Force Base, United StatesSee the site
Where in United States
- Wilford Hall Ambulatory Surgical CenterLackland Air Force Base, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- 59th Medical Wing
- Trial code
- NCT05844384
- Record updated
- 6 May 2023
- Original description
This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.Read full original descriptionShow less
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.
Inclusion: POAG/OHTN patients above the age of 18 years; On a maximum of 2 IOP lowering medications; Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year.
Exclusion: Using more than 2 IOP-lowering medications; IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date; Glaucoma not of the POAG or OHTN variety or other retinal diseases; Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes).